|
1
|
Røssevold AH, Andresen NK, Bjerre CA,
Gilje B, Jakobsen EH, Raj SX, Falk RS, Russnes HG, Jahr T,
Mathiesen RR, et al: Atezolizumab plus anthracycline-based
chemotherapy in metastatic triple-negative breast cancer: The
randomized, double-blind phase 2b ALICE trial. Nat Med.
28:2573–2583. 2022.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Sun M, Shi W, Wu Y, He Z, Sun J, Cai S and
Luo Q: Immunogenic nanovesicle-tandem-augmented chemoimmunotherapy
via efficient cancer-homing delivery and optimized ordinal-interval
regime. Adv Sci (Weinh). 10(e2205247)2022.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Lefrak EA, Pitha J, Rosenheim S and
Gottlieb JA: A clinicopathologic analysis of adriamycin
cardiotoxicity. Cancer. 32:302–314. 1973.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Nemmar A, Al-Salam S, Greish YE, Beegam S,
Zaaba NE and Ali BH: Impact of intratracheal administration of
polyethylene glycol-coated silver nanoparticles on the heart of
normotensive and hypertensive mice. Int J Mol Sci.
24(8890)2023.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Dent SF, Botros J, Rushton M, Aseyev O,
Levine MN, Parulekar WR, O'Brien P, Burnell M, Pritchard KI, Chen
BE and Shepherd LE: Anthracycline-induced cardiotoxicity in
patients with early-stage breast cancer: The Canadian Cancer Trials
Group (CCTG) MA.21 experience. Breast Cancer Res Treat.
184:733–741. 2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Desai VG, Vijay V, Han T, Moland CL,
Phanavanh B, Lee T, Davis KJ, Muskhelishvili L, Stine KC and Fuscoe
JC: Doxorubicin-induced delayed-onset subclinical cardiotoxicity in
mice. J Appl Toxicol. 42:778–792. 2022.PubMed/NCBI View
Article : Google Scholar
|
|
7
|
Zhang Y, Dron JS, Bellows BK, Khera AV,
Liu J, Balte PP, Oelsner EC, Amr SS, Lebo MS, Nagy A, et al:
Association of severe hypercholesterolemia and familial
hypercholesterolemia genotype with risk of coronary heart disease.
Circulation. 147:1556–1559. 2023.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Cosiano MF, Vista A, Sun JL, Alhanti B,
Harrington J, Butler J, Starling RC, Mentz RJ and Greene SJ:
Comparing New York Heart Association class and patient-reported
outcomes among patients hospitalized for heart failure. Circ Heart
Fail. 16(e010107)2023.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Koch T, Lahu S, Coughlan JJ, Cassese S,
Voll F, Ndrepepa G, Menichelli M, Valina C, Hemetsberger R,
Witzenbichler B, et al: Association between platelet count and
treatment effect of ticagrelor or prasugrel in patients with acute
coronary Syndromes. Thromb Haemost. 123:464–477. 2023.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Hwang IC, Choi D, Choi YJ, Ju L, Kim M,
Hong JE, Lee HJ, Yoon YE, Park JB, Lee SP, et al: Differential
diagnosis of common etiologies of left ventricular hypertrophy
using a hybrid CNN-LSTM model. Sci Rep. 12(20998)2022.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Perera D, Clayton T, O'Kane PD, Greenwood
JP, Weerackody R, Ryan M, Morgan HP, Dodd M, Evans R, Canter R, et
al: Percutaneous revascularization for ischemic left ventricular
dysfunction. N Engl J Med. 387:1351–1360. 2022.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Abbasi J: Highlights From the American
College of Cardiology's scientific sessions-new heart failure
management guidelines, alirocumab after a myocardial infarction,
and treating mild chronic hypertension in pregnancy. JAMA.
327:1745–1747. 2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Lima MAC, Brito HRA, Mitidieri GG, de
Souza EP, Sobral ACG, Melo HHMA, Vasconcelos GB, de Almeida BBD,
Figueiredo TAD, Filho MAAS, et al: Cardiotoxicity in cancer
patients treated with chemotherapy: A systematic review. Int J
Health Sci (Qassim). 16:39–46. 2022.PubMed/NCBI
|
|
14
|
Balmagambetova S, Tlegenova Z, Zholdin B,
Kurmanalina G, Talipova I, Koyshybaev A, Nurmanova D, Sultanbekova
G, Baspayeva M, Madinova S, et al: Early diagnosis of
chemotherapy-linked cardiotoxicity in breast cancer patients using
conventional biomarker panel: A prospective study protocol.
Diagnostics (Basel). 12(2714)2022.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Tran DB, AlAshi AK and Hernandez A:
Delayed onset anthracycline-associated cardiotoxicity presenting as
acute decompensated heart failure seven years after chemotherapy
completion. Cureus. 13(e16920)2021.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Von Hoff DD, Layard MW, Basa P, Davis HL
Jr, Von Hoff AL, Rozencweig M and Muggia FM: Risk factors for
doxorubicin-induced congestive heart failure. Ann Intern Med.
91:710–717. 1979.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Ma Jun, Qin Shukui and Shen Zhixiang:
Guidelines for the prevention and treatment of Anthracycline
cardiotoxicity (2013 edition). J Clin Oncol. 18:925–934. 2013.
|
|
18
|
Olson RD and Mushlin PS: Doxorubicin
cardiotoxicity: Analysis of prevailing hypotheses. FASEB J.
4:3076–3086. 1990.PubMed/NCBI
|
|
19
|
Negishi T, Thavendiranathan P, Penicka M,
Lemieux J, Murbraech K, Miyazaki S, Shirazi M, Santoro C, Cho GY,
Popescu BA, et al: Cardioprotection using strain-guided management
of potentially cardiotoxic cancer therapy: 3-year results of the
SUCCOUR Trial. JACC Cardiovasc Imaging. 16:269–278. 2023.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Stěrba M, Popelová O, Vávrová A, Jirkovský
E, Kovaříková P, Geršl V and Simůnek T: Oxidative stress, redox
signaling, and metal chelation in anthracycline cardiotoxicity and
pharmacological cardioprotection. Antioxid Redox Signal.
18:899–929. 2013.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Raj S, Franco VI and Lipshultz SE:
Anthracycline-induced cardiotoxicity: A review of pathophysiology,
diagnosis, and treatment. Curr Treat Options Cardiovasc Med.
16(315)2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Awad HH, El-Derany MO, Mantawy EM, Michel
HE, El-Naa MM, Salah El-Din RA, El-Brairy AI and El-Demerdash E:
Comparative study on beneficial effects of vitamins B and D in
attenuating doxorubicin induced cardiotoxicity in rats: Emphasis on
calcium homeostasis. Biomed Pharmacother.
140(111679)2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Kim SW, Ahn BY, Tran TTV, Pyun JH, Kang JS
and Leem YE: PRMT1 suppresses doxorubicin-induced cardiotoxicity by
inhibiting endoplasmic reticulum stress. Cell Signal.
98(110412)2022.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Pokorná Z, Kollárová-Brázdová P,
Lenčová-Popelová O, Jirkovský E, Kubeš J, Mazurová Y, Adamcová M,
Holečková M, Palička V, Šimůnek T and Štěrba M: Primary prevention
of chronic anthracycline cardiotoxicity with ACE inhibitor is
temporarily effective in rabbits, but benefits wane in
post-treatment follow-up. Clin Sci (Lond). 136:139–161.
2022.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Venturelli F, Masetti R, Fabi M, Rondelli
R, Martoni A, Prete A, Bonvicini M and Pession A: Tissue Doppler
Imaging for anthracycline cardiotoxicity monitoring in pediatric
patients with cancer. Cardiooncology. 4(6)2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Sourdon J, Lager F, Viel T, Balvay D,
Moorhouse R, Bennana E, Renault G, Tharaux PL, Dhaun N and Tavitian
B: Cardiac metabolic deregulation induced by the tyrosine kinase
receptor inhibitor sunitinib is rescued by endothelin receptor
antagonism. Theranostics. 7:2757–2774. 2017.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Nageeb MM, Saadawy SF and Attia SH: Breast
milk mesenchymal stem cells abate cisplatin-induced cardiotoxicity
in adult male albino rats via modulating the AMPK pathway. Sci Rep.
12(17554)2022.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Ruggiero A, De Rosa G, Rizzo D, Leo A,
Maurizi P, De Nisco A, Vendittelli F, Zuppi C, Mordente A and
Riccardi R: Myocardial performance index and biochemical markers
for early detection of doxorubicin-induced cardiotoxicity in
children with acute lymphoblastic leukaemia. Int J Clin Oncol.
18:927–933. 2013.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Mavinkurve-Groothuis AM, Kapusta L, Nir A
and Groot-Loonen J: The role of biomarkers in the early detection
of anthracycline-induced cardiotoxicity in children: A review of
the literature. Pediatr Hematol Oncol. 25:655–664. 2008.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Guo Linjuan, Yu Jianhua, Li Juxiang, et
al: Meta-analysis of continuous slow intravenous infusion and
intravenous bolus administration reducing the risk of cardiac
toxicity of anthracycline drugs. Journal of Clinical Cardiology.
34–39. 2017.(In Chinese).
|
|
31
|
Fox CA and Ryan RO: Studies of the
cardiolipin interactome. Prog Lipid Res. 88(101195)2022.PubMed/NCBI View Article : Google Scholar
|
|
32
|
Wang Zhongtao, Fu Dayian and Wu Zhong:
Analysis of cardioprotective effect of low-dose carvedilol combined
with trimetazidine on breast cancer patients receiving
anthracycline-containing chemotherapy. Chin J Cancer Prev Treat.
43–45. 2020.
|
|
33
|
Janbabai G, Nabati M, Faghihinia M, Azizi
S, Borhani S and Yazdani J: Effect of enalapril on preventing
anthracycline-induced cardiomyopathy. Cardiovasc Toxicol.
17:130–139. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Chotenimitkhun R, D'Agostino R Jr,
Lawrence JA, Hamilton CA, Jordan JH, Vasu S, Lash TL, Yeboah J,
Herrington DM and Hundley WG: Chronic statin administration may
attenuate early anthracycline-associated declines in left
ventricular ejection function. Can J Cardiol. 31:302–307.
2015.PubMed/NCBI View Article : Google Scholar
|
